Ophthalmology
Cohort Study | Retinal artery occlusion linked to a 7-fold higher mortality rate from CV and cerebrovascular diseases
23 Mar, 2023 | 13:04h | UTCSummary: This nationwide cohort study analyzed the incidence of retinal artery occlusion (RAO) in Korea from 2002 to 2018, along with related mortality and causes of death. The incidence of RAO was found to be 7.38 per 100,000 person-years, with a higher incidence of noncentral RAO compared to central RAO.
Patients with RAO had a mortality rate about 7 times higher than the general population, primarily due to cardiovascular or cerebrovascular diseases. The findings emphasize the need to address the risk of cardiovascular or cerebrovascular disease in patients newly diagnosed with RAO.
Invited Commentary: Long-term Management Considerations for Retinal Artery Occlusion and Cardiovascular and Cerebrovascular Mortality – JAMA Network Open
SR | Topical antibiotics modestly improve resolution of acute bacterial conjunctivitis
21 Mar, 2023 | 13:33h | UTCSummary: The Cochrane Review evaluated the benefits and potential side effects of antibiotic therapy in treating acute bacterial conjunctivitis. The authors included 21 randomized controlled trials, with a total of 8,805 participants. The trials evaluated the effectiveness of topical antibiotic treatments in the form of drops or ointments, and were heterogeneous in terms of eligibility criteria, antibiotic drug class, duration of treatment, and outcomes assessed.
The review found that antibiotics likely improved clinical cure by 26% compared with placebo, with no evidence of serious systemic side effects reported in either the antibiotic or placebo group. Fluoroquinolones were found to have fewer ocular side effects compared to non-fluoroquinolones.
Overall, the review suggests that the use of topical antibiotics may be considered to achieve better clinical and microbiologic efficacy than placebo in treating acute bacterial conjunctivitis.
Article: Antibiotics versus placebo for acute bacterial conjunctivitis – Cochrane Library
M-A | Global prevalence of diabetic retinopathy in pediatric type 2 diabetes
20 Mar, 2023 | 13:12h | UTC
SR | Interventions for acute non‐arteritic central retinal artery occlusion
3 Mar, 2023 | 13:36h | UTCInterventions for acute non‐arteritic central retinal artery occlusion – Cochrane Library
Commentary on Twitter
Updated #Cochrane Review finds that treatments for acute non-arteritic #CRAO —the blockage of blood to the retina—are ineffective for visual acuity, and tissue plasminogen activator had serious adverse effectshttps://t.co/RmkLD0te2d@johnclin_ @BrownUResearch @VAResearch pic.twitter.com/BjajHtvWaL
— CochraneEyes (@CochraneEyes) February 2, 2023
SR | Trifocal intraocular lenses vs. bifocal intraocular lenses after cataract extraction among participants with presbyopia
2 Mar, 2023 | 12:46h | UTCSummary: Trifocal versus bifocal lenses implantation after cataract surgery – Cochrane Library
Review | Contact lens–associated keratitis — An often underestimated risk
24 Feb, 2023 | 13:33h | UTCContact Lens–Associated Keratitis— an Often Underestimated Risk – Deutsches Ärzteblatt international
M-A | Interventions for myopia control in children
22 Feb, 2023 | 12:36h | UTCRelated:
RCT | Effect of low-concentration atropine eyedrops vs. placebo on myopia incidence in children
Crossover RCT | Spectacle lenses with highly aspherical lenslets for slowing myopia.
RCT | Effect of text messaging parents of school-aged children on outdoor time to control myopia.
RCT | Myopia control effect of repeated low-level red-light therapy in children.
Phase 2b RCT | Effects of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration
22 Feb, 2023 | 12:21h | UTC
RCT | Effect of low-concentration atropine eyedrops vs. placebo on myopia incidence in children
15 Feb, 2023 | 16:09h | UTCSummary: The study aimed to evaluate the efficacy of low-concentration atropine eyedrops at 0.05% and 0.01% concentration for delaying the onset of myopia in children. The randomized, placebo-controlled, double-masked trial enrolled 474 nonmyopic children aged 4 through 9 years. Participants were assigned to 0.05% atropine, 0.01% atropine, and placebo groups and had eyedrops applied once nightly in both eyes over 2 years. The results showed that the 0.05% atropine eyedrops resulted in a significantly lower incidence of myopia and a lower percentage of participants with fast myopic shift at 2 years compared with placebo. However, there was no significant difference between 0.01% atropine and placebo. More research is necessary to replicate the results, determine whether this approach delays or prevents myopia, and evaluate its long-term safety.*
Article: Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Delaying the Onset of Nearsightedness – JAMA (free for a limited period)
Commentaries:
Atropine Eyedrops Associated With Lower Incidence of Myopia, Myopic Shift – AJMC
Low-Concentration Atropine Eyedrops Linked to Lower Myopia Incidence in Children – HCP Live
0.05 Percent Atropine Eye Drops Result in Lower Incidence of Myopia – HealthDay
Commentary on Twitter
Among children aged 4 to 9 years without #myopia, nightly use of 0.05% atropine eyedrops compared with placebo resulted in a significantly lower incidence of myopia and lower percentage of participants with fast myopic shift at 2 years. https://t.co/XUjnPVGVad pic.twitter.com/4iZa4Iek76
— JAMA (@JAMA_current) February 14, 2023
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
M-A | Prevalence of ocular candidiasis and Candida endophthalmitis in patients with candidemia
14 Feb, 2023 | 10:43h | UTC
Commentary on Twitter
Prevalence of ocular candidiasis and Candida endophthalmitis in patients with candidemia: A systematic review and meta-analysis
✅ Just Accepted
🆓 Freely Available
🔗 https://t.co/a8SYDUM8UH pic.twitter.com/L5niNTVIUd— Clinical Infectious Diseases (@CIDJournal) February 9, 2023
Review | Anisocoria in the ED: pathophysiology, evaluation, and management
14 Feb, 2023 | 10:41h | UTCAnisocoria in the ED: Pathophysiology, Evaluation, and Management – emDocs
52-week results from two phase III trials of brolucizumab for diabetic macular edema
8 Feb, 2023 | 12:25h | UTC
Childhood blindness incidence and etiologies trends in Israel 2014–2020: what should we focus on?
1 Feb, 2023 | 12:59h | UTC
Cohort Study | Association of retinal age gap and risk of kidney failure
31 Jan, 2023 | 13:38h | UTCNews Release: Aging in the eye predicts risk for kidney failure – National Kidney Foundation
Related:
Association of Retinal Age Gap With Arterial Stiffness and Incident Cardiovascular Disease – Stroke
Commentary on Twitter
Association of Retinal Age Gap and Risk of Kidney Failure: A UK Biobank Study https://t.co/SvU6QrDSYw #OpenAccess#VisualAbstract pic.twitter.com/5iQqF28kEW
— AJKD (@AJKDonline) December 10, 2022
Cross-Sectional Study | Association of maternal and paternal astigmatism with child astigmatism
31 Jan, 2023 | 13:35h | UTC
Cohort Study | Association between rate of ganglion cell complex thinning and rate of central visual field loss
31 Jan, 2023 | 13:33h | UTCAssociation Between Rate of Ganglion Cell Complex Thinning and Rate of Central Visual Field Loss – JAMA Ophthalmology (link to abstract – $ for full-text)
Commentaries:
Rapid Initial GCC Thinning Associated with Faster Rates of Central Visual Field Loss – HCP Live
Ganglion Cell Complex Thinning Associated With Faster Central Visual Field Decline – AJMC
Early detection of visual impairment in young children using a smartphone-based deep learning system
30 Jan, 2023 | 01:12h | UTC
Commentary on Twitter
A #smartphone-based system, designed to induce a steady #gaze in children using cartoon-like video stimuli, can identify visually-impaired children across a wide range of #ophthalmic disorders, based on analysis of gazing behaviors and facial featureshttps://t.co/V9s5SioYXZ
— Nature Medicine (@NatureMedicine) January 27, 2023
Evaluation of systemic medications associated with surgically treated cataract among US adults
30 Jan, 2023 | 00:38h | UTCCommentary: Some systemic medications may be associated with increased cataract risk – 2 Minute Medicine
Cohort Study | Estimating the length of the preclinical detectable phase for open-angle glaucoma
26 Jan, 2023 | 12:00h | UTCEstimating the Length of the Preclinical Detectable Phase for Open-Angle Glaucoma – JAMA Ophthalmology (link to abstract – $ for full-text)
Commentaries:
Mean Length of Preclinical Detectable Phase for Open-Angle Glaucoma Estimated at 10 Years – HCP Live
Mean Length of Preclinical Detectable Phase of Glaucoma >10 Years – HealthDay
Commentary on Twitter
Population-based study in Sweden suggests the average time from which glaucoma can be detected by screening to its clinical diagnosis is approximately 10 years, supporting screening intervals of 5 years. https://t.co/JfQciIjJBw
— JAMA Ophthalmology (@JAMAOphth) November 24, 2022
RCT | Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular edema
24 Jan, 2023 | 14:02h | UTCOriginal Publication: Diabetic Macular Edema and Diode Subthreshold Micropulse Laser: A Randomized Double-Masked Noninferiority Clinical Trial – Ophthalmology
Cohort Study | Hydroxychloroquine dose and risk for incident retinopathy
18 Jan, 2023 | 14:21h | UTCHydroxychloroquine Dose and Risk for Incident Retinopathy: A Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: Long-term low-dose hydroxychloroquine use associated with low risk for retinopathy – American College of Physicians
Commentary: Long-term low-dose hydroxychloroquine use associated with low risk for retinopathy – ACP Internist
M-A | Outcomes and complications of pars plana vitrectomy for tractional retinal detachment in people with diabetes
15 Jan, 2023 | 20:02h | UTCCommentary: Pars Plana Vitrectomy Associated with High Retinal Reattachment, but Low Final Vision – HCP Live
Commentary on Twitter
Study findings suggest that pars plana vitrectomy is associated with high anatomic reattachment but limited final vision postoperatively, which may be useful for the counseling of patients with diabetic tractional retinal detachment. https://t.co/Comj3VOpUF
— JAMA Ophthalmology (@JAMAOphth) January 12, 2023
SR | Laser therapy for retinopathy in sickle cell disease
12 Jan, 2023 | 13:02h | UTCLaser therapy for retinopathy in sickle cell disease – Cochrane Library
Summary: Laser therapy for retinopathy in sickle cell disease – Cochrane Library
SR | Non‐steroidal anti‐inflammatory agents for treating cystoid macular edema following cataract surgery
11 Jan, 2023 | 13:57h | UTC
SR | Design and conduct of randomized clinical trials evaluating surgical innovations in ophthalmology
10 Jan, 2023 | 14:04h | UTCDesign and conduct of randomized clinical trials evaluating surgical innovations in ophthalmology: A systematic review – American Journal of Ophthalmology (free for a limited period)